Federico Innocenti

Federico Innocenti

University of North Carolina Chapel Hill - Chapel Hill / United States
Others
AD Scientific Index ID: 1586808
person_outline Federico Innocenti's MOST POPULAR ARTICLES
1-) Comprehensive and integrative genomic characterization of hepatocellular carcinomaA Ally, M Balasundaram, R Carlsen, E Chuah, A Clarke, N Dhalla, RA Holt, ...Cell 169 (7), 1327-1341. e23, 201714302017
2-) Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of IrinotecanF Innocenti, SD Undevia, L Iyer, P Xian Chen, S Das, M Kocherginsky, ...Journal of Clinical Oncology 22 (8), 1382-1388, 200411082004
3-) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)HL Kindler, D Niedzwiecki, D Hollis, S Sutherland, D Schrag, H Hurwitz, ...Journal of Clinical Oncology 28 (22), 3617, 20109352010
4-) Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a …AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ...Jama 317 (23), 2392-2401, 20178962017
5-) CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts …AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, MR Mahoney, BH O\'Neil, ...Journal of Clinical Oncology 32 (15_suppl), LBA3-LBA3, 20146162014